Overview
The marketing authorisation for Clopidogrel Ratiopharm GmbH has been withdrawn at the request of the marketing-authorisation holder.
Clopidogrel ratiopharm GmbH : EPAR - Summary for the public
English (EN)
(619.48 KB - PDF)View
български (BG)
(748.14 KB - PDF)
español (ES)
(699.21 KB - PDF)
čeština (CS)
(774.98 KB - PDF)
dansk (DA)
(698.71 KB - PDF)
Deutsch (DE)
(699.89 KB - PDF)
eesti keel (ET)
(698.1 KB - PDF)
ελληνικά (EL)
(816.71 KB - PDF)
français (FR)
(697.65 KB - PDF)
italiano (IT)
(736.11 KB - PDF)
latviešu valoda (LV)
(717.15 KB - PDF)
lietuvių kalba (LT)
(696.28 KB - PDF)
magyar (HU)
(748.24 KB - PDF)
Malti (MT)
(773.38 KB - PDF)
Nederlands (NL)
(699.22 KB - PDF)
polski (PL)
(774.48 KB - PDF)
português (PT)
(639.16 KB - PDF)
română (RO)
(664.03 KB - PDF)
slovenčina (SK)
(771.09 KB - PDF)
slovenščina (SL)
(766.49 KB - PDF)
Suomi (FI)
(692.08 KB - PDF)
svenska (SV)
(698.39 KB - PDF)
Product information
Clopidogrel ratiopharm GmbH : EPAR - Product Information
English (EN)
(900.55 KB - PDF)View
български (BG)
(2.02 MB - PDF)
español (ES)
(1.05 MB - PDF)
čeština (CS)
(1.71 MB - PDF)
dansk (DA)
(1.05 MB - PDF)
Deutsch (DE)
(1.08 MB - PDF)
eesti keel (ET)
(1.07 MB - PDF)
ελληνικά (EL)
(2.07 MB - PDF)
français (FR)
(1.12 MB - PDF)
hrvatski (HR)
(1.14 MB - PDF)
íslenska (IS)
(1.04 MB - PDF)
italiano (IT)
(1.06 MB - PDF)
latviešu valoda (LV)
(1.71 MB - PDF)
lietuvių kalba (LT)
(1.15 MB - PDF)
magyar (HU)
(1.81 MB - PDF)
Malti (MT)
(1.93 MB - PDF)
Nederlands (NL)
(1.08 MB - PDF)
norsk (NO)
(1.03 MB - PDF)
polski (PL)
(960.36 KB - PDF)
português (PT)
(1.05 MB - PDF)
română (RO)
(1.2 MB - PDF)
slovenčina (SK)
(1.68 MB - PDF)
slovenščina (SL)
(1.64 MB - PDF)
Suomi (FI)
(886.54 KB - PDF)
svenska (SV)
(1.1 MB - PDF)
Latest procedure affecting product information: IAIN/0036
22/08/2019
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Clopidogrel ratiopharm GmbH : EPAR - All Authorised presentations
English (EN)
(574.5 KB - PDF)View
български (BG)
(1.2 MB - PDF)
español (ES)
(1.12 MB - PDF)
čeština (CS)
(1.19 MB - PDF)
dansk (DA)
(1.12 MB - PDF)
Deutsch (DE)
(1.12 MB - PDF)
eesti keel (ET)
(1.12 MB - PDF)
ελληνικά (EL)
(1.2 MB - PDF)
français (FR)
(1.12 MB - PDF)
italiano (IT)
(1.12 MB - PDF)
latviešu valoda (LV)
(1.2 MB - PDF)
lietuvių kalba (LT)
(1.18 MB - PDF)
magyar (HU)
(1.2 MB - PDF)
Malti (MT)
(1.19 MB - PDF)
Nederlands (NL)
(1.12 MB - PDF)
polski (PL)
(1.16 MB - PDF)
português (PT)
(1.12 MB - PDF)
română (RO)
(1.18 MB - PDF)
slovenčina (SK)
(1.16 MB - PDF)
slovenščina (SL)
(1.13 MB - PDF)
Suomi (FI)
(1.12 MB - PDF)
svenska (SV)
(1.12 MB - PDF)
Product details
- Name of medicine
- Clopidogrel ratiopharm GmbH
- Active substance
- clopidogrel
- International non-proprietary name (INN) or common name
- clopidogrel
- Therapeutic area (MeSH)
- Peripheral Vascular Diseases
- Acute Coronary Syndrome
- Myocardial Infarction
- Stroke
- Anatomical therapeutic chemical (ATC) code
- B01AC04
Pharmacotherapeutic group
Antithrombotic agentsTherapeutic indication
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
- patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;
- patients suffering from acute coronary syndrome:
- non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q wave-myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);
- ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Assessment history
This page was last updated on